- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/44 - GlucocorticosteroidsDrugs increasing or potentiating the activity of glucocorticosteroids
Patent holdings for IPC class A61P 5/44
Total number of patents in this class: 132
10-year publication summary
|
1
|
4
|
2
|
4
|
4
|
8
|
5
|
13
|
8
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Corcept Therapeutics, Inc. | 338 |
6 |
| Nicox S.A. | 138 |
6 |
| Ardelyx, Inc. | 113 |
5 |
| Chiesi Farmaceutici S.p.A. | 969 |
5 |
| Gilead Sciences, Inc. | 2036 |
4 |
| Santen Pharmaceutical Co., Ltd. | 600 |
3 |
| Schering Corporation | 453 |
3 |
| Mallinckrodt ARD IP Limited | 8 |
3 |
| Glaxo Group Limited | 4071 |
2 |
| Merck & Co., Inc. | 331 |
2 |
| Boehringer Ingelheim International GmbH | 4650 |
2 |
| Boehringer Ingelheim Pharma GmbH & Co. Kg | 570 |
2 |
| Board of Regents, The University of Texas System | 5793 |
2 |
| Aerie Pharmaceuticals, Inc. | 50 |
2 |
| Board of Regents of the University of Nebraska | 759 |
2 |
| Case Western Reserve University | 1821 |
2 |
| DuoCort Pharma AB | 2 |
2 |
| Eli Lilly and Company | 3842 |
2 |
| Generics [UK] Limited | 127 |
2 |
| MetrioPharm AG | 48 |
2 |
| Other owners | 73 |